- World
Anti-Doping Agency (WADA) removes CBD from banned substances list
- Art
‘One Glove’ Jimmerson appointed brand ambassador for CBD Fitamins line
- Hemp
CBD market projected to maintain 55 percent CAGR to 2020
In sports, as the saying goes, there’s no gain without pain.
However, not all pain is the same, at least according to researchers at the
John Hopkins School of Medicine (http://ibn.fm/rVGLo).
They note that there is good pain and bad pain. Stress in the muscles as they
develop strength causes the former, but excessive training can overload and
damage muscles, resulting in bad pain. Regardless of taxonomy, pain is an
athlete’s constant companion, and, in the search for more effective escapes
from it, many are ditching traditional anodynes and turning to cannabidiol
(CBD) products like those provided by Cannabis Strategic Ventures, Inc. (OTC:
NUGS). The company is offering athletes a way to ease their pain with its
Fitamins CBD line. It recently signed Art ‘One Glove’ Jimmerson to be brand
ambassador for the label (http://ibn.fm/Ggn62).
Jimmerson knows a thing or two about pain. He is a former
professional boxer and mixed martial arts fighter, as well as a pioneer of the
Ultimate Fighting Championship (UFC) franchise. His appointment as brand
ambassador was announced on November 10 at the UFC 25th Anniversary Fight Night
in Denver, Colorado, an event that was viewed by millions of fans. Jimmerson’s
journey in contact sports took flight in 1983, while still an amateur, after he
became the National Golden Gloves Middleweight champion. He went on to achieve
an admirable record of 51-18 over a 20-year career that lasted from 1983 to
2002.
Cannabinoids are gaining increasing prominence as acceptable
alternatives to traditional analgesics, such as ibuprofen and acetaminophen,
with THC and CBD garnering the most attention. Depending on jurisdiction, a
variety of restrictions on the use of THC, some of which also limit the
availability of CBD, exist, although, since CBD has no psychotropic effect,
regulation of CBD tends to be less restrictive than for THC. The advantages of
CBD are that it offers some of the same medical benefits (anti-inflammatory,
anti-anxiety, analgesic effects) as THC, but without the legal and
psychological complications.
CBD has an effect on the brain’s serotonin and vanilloid
receptors, and it thus lightens mood and the perception of pain. It also acts
as an antioxidant, neutralizing free radicals in the body that damage tissues
and cells by “stealing” their electrons (http://ibn.fm/BNxU7). As such, its therapeutic value is
increasingly being recognized, and, in January 2018, the World Anti-Doping
Agency (WADA) removed CBD from its list of banned substances (http://ibn.fm/6EkF2). This
clears the way for the Fitamins line to be marketed to the sports industry.
Fitamins is a proprietary health and wellness formula
containing 25 mg of hemp-derived, THC-free CBD and other joint supporting
vitamins that work to improve health and relieve joint and muscle pain,
encouraging movement and flexibility.
NUGS acquired the Fitamins CBD brand in August 2018 (http://ibn.fm/3PcG2). Products
under the brand consist of vitamin and hemp-derived CBD formulations, which
will be distributed through Fitamins’ network of 600+ wholesalers catering to
the Asian-American market. The agreement between the companies calls for
Fitamins to produce a proprietary CBD product as part of NUGS’ brand portfolio,
initially targeting United States distribution networks and eventually
expanding into Asian markets that have legalized CBD products.
The market for CBD therapies is buoyant. Hemp-derived CBD
sales are ballooning at a CAGR of 55 percent. They are set to hit $1 billion by
2020. As word spreads on the field about CBD’s effectiveness in treating pain,
expect the Fitamins brand to get a place on the team.
For more information, visit the company’s website at www.CannabisStrategic.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
